Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15380544 | 0.84 | CHRM3 (0.36) | TDP1MCL1ALDH1A1LMNA | |
| SCHEMBL6136497 | 0.81 | EPHX2 (0.42) | KDM4EKMT2ATDP1EPHX2MCL1 | |
| SCHEMBL6136623 | 0.81 | EPHX2 (0.42) | KDM4EKMT2ATDP1EPHX2MCL1 | |
| SCHEMBL6136501 | 0.81 | EPHX2 (0.42) | KDM4EKMT2ATDP1EPHX2MCL1 | |
| SCHEMBL4317053 | 0.80 | MMP2 (0.52) | KDM4EKMT2ATDP1EPHX2MCL1 | |
| SCHEMBL4317049 | 0.80 | MMP2 (0.52) | KDM4EKMT2ATDP1EPHX2MCL1 | |
| SCHEMBL4795920 | 0.80 | MMP2 (0.52) | KDM4EKMT2ATDP1EPHX2MCL1 | |
| SCHEMBL4313544 | 0.77 | MCL1 (0.53) | MCL1ALDH1A1LMNAMAPT | |
| SCHEMBL4313540 | 0.77 | MCL1 (0.53) | MCL1ALDH1A1LMNAMAPT | |
| SCHEMBL6847022 | 0.77 | MCL1 (0.53) | MCL1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187472-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303511-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | KDM4E 3407/4885KMT2A 2175/4885TDP1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.